Has the U.S. Drug Retail Industry valuation changed over the past few years?

Investors are pessimistic on the American Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading close to its 3-year average PS ratio of 0.12x.

How does U.S. Drug Retail compare with similar industries?

There are no additional sub-industries under this industry.

U.S. Drug Retail Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 19 Jun 2026	US$124.8m	US$1.9b	-US$59,313,056.33	n/a	-2.1x	0.07x
Sun, 17 May 2026	US$113.5m	US$2.0b	-US$57,829,112.34	n/a	-2x	0.06x
Tue, 14 Apr 2026	US$120.5m	US$2.0b	-US$53,306,252.36	n/a	-2.3x	0.06x
Thu, 12 Mar 2026	US$147.9m	US$2.2b	-US$52,333,881.80	15.7x	-2.8x	0.07x
Sat, 07 Feb 2026	US$124.5m	US$2.1b	-US$34,427,426.09	13.8x	-3.6x	0.06x
Mon, 05 Jan 2026	US$95.4m	US$2.1b	-US$34,349,079.85	24x	-2.8x	0.05x
Wed, 03 Dec 2025	US$98.5m	US$2.2b	-US$34,824,315.28	18.9x	-2.8x	0.05x
Fri, 31 Oct 2025	US$1.9b	US$3.5b	-US$120,257,004.03	24.2x	-15.8x	0.5x
Sun, 28 Sep 2025	US$1.7b	US$3.5b	-US$120,223,236.21	20.7x	-14.5x	0.5x
Tue, 26 Aug 2025	US$12.2b	US$158.1b	-US$6,417,424,352.84	18.9x	-1.9x	0.08x
Thu, 24 Jul 2025	US$11.5b	US$158.1b	-US$6,426,950,213.88	39.4x	-1.8x	0.07x
Sat, 21 Jun 2025	US$11.2b	US$155.4b	-US$5,908,389,288.29	n/a	-1.9x	0.07x
Mon, 19 May 2025	US$11.4b	US$155.4b	-US$5,906,493,038.11	n/a	-1.9x	0.07x
Wed, 16 Apr 2025	US$11.0b	US$155.3b	-US$5,913,738,184.70	n/a	-1.9x	0.07x
Fri, 14 Mar 2025	US$11.0b	US$153.8b	-US$8,983,749,049.72	n/a	-1.2x	0.07x
Sun, 09 Feb 2025	US$10.2b	US$153.8b	-US$8,983,538,278.02	n/a	-1.1x	0.07x
Tue, 07 Jan 2025	US$9.5b	US$151.0b	-US$8,784,037,604.25	n/a	-1.1x	0.06x
Thu, 05 Dec 2024	US$9.4b	US$151.0b	-US$8,784,305,039.21	n/a	-1.1x	0.06x
Sat, 02 Nov 2024	US$9.4b	US$151.0b	-US$8,683,653,794.68	81.8x	-1.1x	0.06x
Mon, 30 Sep 2024	US$9.0b	US$149.0b	-US$5,878,915,716.20	78x	-1.5x	0.06x
Wed, 28 Aug 2024	US$8.3b	US$147.8b	-US$5,898,369,007.16	n/a	-1.4x	0.06x
Fri, 26 Jul 2024	US$9.8b	US$147.8b	-US$5,905,739,086.29	n/a	-1.7x	0.07x
Sun, 23 Jun 2024	US$13.9b	US$146.9b	-US$6,131,584,509.17	n/a	-2.3x	0.09x
Tue, 21 May 2024	US$15.9b	US$146.9b	-US$6,133,304,956.22	38.5x	-2.6x	0.1x
Thu, 18 Apr 2024	US$15.4b	US$146.9b	-US$6,142,337,629.68	38.5x	-2.5x	0.1x
Sat, 16 Mar 2024	US$18.0b	US$144.7b	US$499.5m	31.3x	36x	0.1x
Mon, 12 Feb 2024	US$19.4b	US$144.7b	US$499.3m	33.4x	38.8x	0.1x
Wed, 10 Jan 2024	US$22.1b	US$144.7b	US$444.9m	38.1x	49.6x	0.2x
Fri, 08 Dec 2023	US$18.7b	US$141.4b	-US$3,209,275,293.00	45.3x	-5.8x	0.1x
Sun, 05 Nov 2023	US$19.4b	US$164.8b	-US$4,853,479,314.00	67.3x	-4x	0.1x
Tue, 03 Oct 2023	US$19.5b	US$138.4b	-US$3,448,547,869.00	361.3x	-5.7x	0.1x
Thu, 31 Aug 2023	US$22.4b	US$138.4b	-US$3,448,645,558.00	361.3x	-6.5x	0.2x
Sat, 29 Jul 2023	US$26.9b	US$138.4b	-US$3,449,030,515.00	361.3x	-7.8x	0.2x
Mon, 26 Jun 2023	US$27.5b	US$135.5b	-US$3,277,999,295.00	n/a	-8.4x	0.2x


US Market	1.65%
Consumer Staples	-2.33%
Food and Staples Retail	-2.84%
Drug Retail	-4.01%
Food Distributors	-0.027%
Big Box Super Stores	-2.61%
Food Retail	-7.84%

	Company	Last Price	7D	1Y	Valuation
No data available

Announcement • 4h

EMJ Crypto Technologies completed the acquisition of SRx Health Solutions Inc. (NYSEAM:SRXH) in a reverse merger transaction.

EMJ Crypto Technologies entered into a definitive agreement to acquire SRx Health Solutions Inc. (NYSEAM:SRXH) in a reverse merger transaction on December 16, 2025. Upon completion, the EMJX platform will operate through a wholly-owned subsidiary of the Company. Following completion, the combined company expects to operate under the EMJX name and intends to pursue a ticker symbol change, subject to exchange approval. Until closing, SRx Health shares will continue to trade on NYSE American under the symbol SRXH. On December 17, 2025, the change of the legal name of the Company from “SRx Health Solutions, Inc.” to “EMJX, Inc.” and of the NYSE ticker symbol from “SRXH” to “EMJX”, in each case conditioned upon the closing of the transaction. In case of termination, SRx Health Solutions Inc or EMJ will pay $0.3 million. Upon completion of the transaction, Eric M. Jackson, Founder and Chief Executive Officer of EMJ Crypto Technologies, is expected to serve as Chief Executive Officer and Chairman of the combined company. As per filling of April 17, 2026, Eric. M. Jackson will be appointed as an officer of the Company’s EMJC subsidiary following the merger. The transaction is subject to approval by SRx Health Solutions shareholders, Effectiveness of registration statement, listing approval, board approval and regulatory approvals. The deal has been unanimously approved by both boards. The transaction is expected to complete during the first quarter of 2026. The transaction is expected to close in the second quarter of 2026. On March 18, 2026, SRx Health Solutions and EMJ Crypto entered into a hedged position on its cryptocurrency and emerging markets investment portfolio for volatility protection on digital assets and international revenues. SRx Health Solutions will update shareholders in the near future on the proposed timing to close the EMJ transaction. Registration Statement on Form S-4 (File No. 333-295154) declared effective by the Securities and Exchange Commission (“ SEC ”) on May 7, 2026. Louis Lombardo of Meister Seelig & Fein LLP acted as legal advisor to SRx Health Solutions and Matt McLeod of Dickinson Wright PLLC acted as legal advisor to EMJ CRYPTO TECHNOLOGIES INC. Equity Stock Transfer, LLC acted as transfer agent to SRx Health Solutions Inc. Hyperion Capital Inc acted as fairness opinion provider to SRx Health Solutions. EMJ Crypto Technologies completed the acquisition of SRx Health Solutions Inc. (NYSEAM:SRXH) in a reverse merger transaction on June 18, 2026. In conjunction with the transaction closing, the Company has changed its legal name and branding to SRX Global Inc. The Company’s stock will remain trading on the NYSE under the ticker symbol “SRXH” and will continue to trade under the existing name for up to 10 business days. The management team of the newly merged company will comprise Kent Cunningham as Chief Executive Officer, Eric Jackson, PhD, as President, EMJX & Head of Asset Management, and Nina Martinez as Chief Financial Officer.

U.S. Drug Retail Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

EMJ Crypto Technologies completed the acquisition of SRx Health Solutions Inc. (NYSEAM:SRXH) in a reverse merger transaction.

First quarter 2026 earnings released: CN¥4.21 loss per share (vs CN¥2.04 loss in 1Q 2025)

Mangoceuticals, Inc. announced delayed 10-Q filing

New major risk - Market cap size